N3-substituted thymidine bioconjugates for cancer therapy and imaging.

The compound class of 3-carboranyl thymidine analogues (3CTAs) are boron delivery agents for boron neutron capture therapy (BNCT), a binary treatment modality for cancer. Presumably, these compounds accumulate selectively in tumor cells via intracellular trapping, which is mediated by hTK1. Favorable in vivo biodistribution profiles of 3CTAs led to promising results in preclinical BNCT of rats with intracerebral brain tumors. This review presents an overview on the design, synthesis, and biological evaluation of first- and second-generation 3CTAs. Boronated nucleosides developed prior to 3CTAs for BNCT and non-boronated N3-substituted thymidine conjugates for other areas of cancer therapy and imaging are also described. In addition, basic features of carborane clusters, which are used as boron moieties in the design and synthesis of 3CTAs, and the biological and structural features of TK1-like enzymes, which are the molecular targets of 3CTAs, are discussed.

[1]  H. Agarwal,et al.  Synthesis of N3-substituted carboranyl thymidine bioconjugates and their evaluation as substrates of recombinant human thymidine kinase 1. , 2013, European journal of medicinal chemistry.

[2]  H. Agarwal,et al.  Synthesis, chemical and enzymatic hydrolysis, and aqueous solubility of amino acid ester prodrugs of 3-carboranyl thymidine analogs for boron neutron capture therapy of brain tumors. , 2012, European journal of medicinal chemistry.

[3]  L. Carroll,et al.  Synthesis and evaluation of nucleoside radiotracers for imaging proliferation. , 2012, Nuclear medicine and biology.

[4]  F. Gago,et al.  Recent advances in thymidine kinase 2 (TK2) inhibitors and new perspectives for potential applications. , 2012, Current pharmaceutical design.

[5]  K. Jagarlamudi,et al.  Quaternary structures of recombinant, cellular, and serum forms of Thymidine Kinase 1 from dogs and humans , 2012, BMC Biochemistry.

[6]  H. Agarwal,et al.  Synthesis, biological evaluation, and radioiodination of halogenated closo-carboranylthymidine analogues. , 2012, Inorganic chemistry.

[7]  J. Christensen,et al.  [18F]FLT–PET Imaging Does Not Always “Light Up” Proliferating Tumor Cells , 2011, Clinical Cancer Research.

[8]  I. Sivaev,et al.  Synthesis of conjugates of polyhedral boron compounds with tumor-seeking molecules for neutron capture therapy. , 2011, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[9]  I. Sivaev,et al.  Polyhedral Boron Compounds for BNCT , 2011 .

[10]  H. Agarwal,et al.  Boron Cluster (Radio)Halogenation in Biomedical Research , 2011 .

[11]  N. Hosmane.  Boron Science : New Technologies and Applications , 2011 .

[12]  E. Hey‐Hawkins,et al.  Carbaboranes as pharmacophores: properties, synthesis, and application strategies. , 2011, Chemical reviews.

[13]  M. Kassiou,et al.  Boron in drug discovery: carboranes as unique pharmacophores in biologically active compounds. , 2011, Chemical reviews.

[14]  J. Zubieta,et al.  Synthesis, cytotoxicity and cellular uptake studies of N3 functionalized Re(CO)3 thymidine complexes. , 2011, Dalton transactions.

[15]  J. Zubieta,et al.  Synthesis, Cytotoxicity, and Insight into the Mode of Action of Re(CO)3 Thymidine Complexes , 2010, ChemMedChem.

[16]  R. Schibli,et al.  Charge dependent substrate activity of C3' and N3 functionalized, organometallic technetium and rhenium-labeled thymidine derivatives toward human thymidine kinase 1. , 2010, Bioconjugate chemistry.

[17]  G. Ricciardi,et al.  Carborane derivatives loaded into liposomes as efficient delivery systems for boron neutron capture therapy. , 2009, Journal of medicinal chemistry.

[18]  A. V. Orlova,et al.  Synthesis of conjugates of polyhedral boron compounds with carbohydrates , 2009 .

[19]  R. Barth,et al.  Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents. , 2009, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[20]  G. Miotto,et al.  A novel boronated-porphyrin as a radio-sensitizing agent for boron neutron capture therapy of tumours: in vitro and in vivo studies. , 2009, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[21]  R. Schibli,et al.  Organometallic [Re(CO)3]+ and [Re(CO)2(NO)]2+ labeled substrates for human thymidine kinase 1. , 2009, Inorganic chemistry.

[22]  I. Godovikov,et al.  Synthesis of closo-dodecaborate based nucleoside conjugates , 2009 .

[23]  H. Struthers.  Click-to chelate , 2009 .

[24]  J. Gelovani,et al.  N3-Substituted Thymidine Analogues: Radiosyntheses of N3-[4-(4-(2-[18F] fluoroethyl)phenyl)butyl]thymidine and N3-[5-(4-(2-[18F]fluoroethyl)- phenyl)pentyl]thymidine for PET , 2009 .

[25]  Yongbing Sun,et al.  Synthesis, transport and pharmacokinetics of 5'-amino acid ester prodrugs of 1-beta-D-arabinofuranosylcytosine. , 2009, Molecular pharmaceutics.

[26]  B. Grüner,et al.  "Chemical ligation": a versatile method for nucleoside modification with boron clusters. , 2008, Chemistry.

[27]  M. Moeschberger,et al.  Thymidine kinase 1 as a molecular target for boron neutron capture therapy of brain tumors , 2008, Proceedings of the National Academy of Sciences.

[28]  V. Spiwok,et al.  Synthesis, in vitro, and in silico evaluation of organometallic technetium and rhenium thymidine complexes with retained substrate activity toward human thymidine kinase type 1. , 2008, Journal of medicinal chemistry.

[29]  W. Bornmann,et al.  Synthesis of N3-substituted thymidine analogues for measurement of cellular kinase activity. , 2008, Medicinal chemistry (Shariqah (United Arab Emirates)).

[30]  J. Gelovani,et al.  N(3)-Substituted thymidine analogues V: synthesis and preliminary PET imaging of N(3)-[(18)F]fluoroethyl thymidine and N(3)-[(18)F]fluoropropyl thymidine. , 2008, Nuclear medicine and biology.

[31]  R. Schibli,et al.  "Click-to-chelate": design and incorporation of triazole-containing metal-chelating systems into biomolecules of diagnostic and therapeutic interest. , 2008, Chemistry.

[32]  B. Vig,et al.  Enhanced Absorption and Growth Inhibition with Amino Acid Monoester Prodrugs of Floxuridine by Targeting hPEPT1 Transporters , 2008, Molecules.

[33]  Youngjoo Byun,et al.  Carboranyl Thymidine Analogues for Neutron Capture Therapy , 2008 .

[34]  M. Moeschberger,et al.  Molecular Targeting and Treatment of Composite EGFR and EGFRvIII-Positive Gliomas Using Boronated Monoclonal Antibodies , 2008, Clinical Cancer Research.

[35]  M. Konrad,et al.  Quaternary structure change as a mechanism for the regulation of thymidine kinase 1-like enzymes. , 2007, Structure.

[36]  R. Schibli,et al.  Strategies for the Development of Novel Tumor Targeting Technetium and Rhenium Radiopharmaceuticals , 2007 .

[37]  J. Gelovani,et al.  N3‐Substituted thymidine analogues III: radiosynthesis of N3‐[(4‐[18F]fluoromethyl‐phenyl)butyl]thymidine ([18F]‐FMPBT) and N3‐[(4‐[18F]fluoromethyl‐phenyl)pentyl] thymidine ([18F]‐FMPPT) for PET , 2007 .

[38]  K. Edwards,et al.  Synthesis, liposomal preparation, and in vitro toxicity of two novel dodecaborate cluster lipids for boron neutron capture therapy. , 2007, Bioconjugate chemistry.

[39]  C. Monnerjahn,et al.  Binding of ATP to TK1-like enzymes is associated with a conformational change in the quaternary structure. , 2007, Journal of molecular biology.

[40]  J. Nuyts,et al.  Synthesis and evaluation of a (99m)Tc-MAMA-propyl-thymidine complex as a potential probe for in vivo visualization of tumor cell proliferation with SPECT. , 2007, Nuclear medicine and biology.

[41]  L. Rendina,et al.  Boronated DNA-binding compounds as potential agents for boron neutron capture therapy. , 2007, Mini reviews in medicinal chemistry.

[42]  H. Eklund,et al.  Structural studies of thymidine kinases from Bacillus anthracis and Bacillus cereus provide insights into quaternary structure and conformational changes upon substrate binding , 2007, The FEBS journal.

[43]  M. Vicente,et al.  Recent Progress in the Syntheses and Biological Evaluation of Boronated Porphyrins for Boron Neutron‐Capture Therapy , 2006 .

[44]  J. Gelovani,et al.  Synthesis of [18F]-labeled N-3(substituted) thymidine analogues : N-3([18F]fluorobutyl) thymidine ([18F]-FBT) and N-3([18F]fluoropentyl) thymidine ([18F]-FPT) for PET , 2006 .

[45]  D. Stammers,et al.  BMC Structural Biology BioMed Central , 2006 .

[46]  S. Eriksson,et al.  Hydrophilically enhanced 3-carboranyl thymidine analogues (3CTAs) for boron neutron capture therapy (BNCT) of cancer. , 2006, Bioorganic & medicinal chemistry.

[47]  M. J. Newman,et al.  Kinase-mediated trapping of bi-functional conjugates of paclitaxel or vinblastine with thymidine in cancer cells. , 2006, Bioorganic & medicinal chemistry letters.

[48]  S. Eriksson,et al.  Preparation and biological evaluation of 10B-enriched 3-[5-{2-(2,3-dihydroxyprop-1-yl)-o-carboran-1-yl}pentan-1-yl]thymidine (N5-2OH), a new boron delivery agent for boron neutron capture therapy of brain tumors. , 2006, Journal of medicinal chemistry.

[49]  S. Eriksson,et al.  Boronated Thymidine Analogues for Boron Neutron Capture Therapy , 2006, Nucleosides, nucleotides & nucleic acids.

[50]  Y. Fujibayashi,et al.  Alkyl-fluorinated thymidine derivatives for imaging cell proliferation II. Synthesis and evaluation of N3-(2-[18F]fluoroethyl)-thymidine. , 2006, Nuclear medicine and biology.

[51]  Y. Fujibayashi,et al.  Alkyl-fluorinated thymidine derivatives for imaging cell proliferation I. The in vitro evaluation of some alkyl-fluorinated thymidine derivatives. , 2006, Nuclear medicine and biology.

[52]  F. Mottaghy,et al.  Synthesis and evaluation of a radiometal-labeled macrocyclic chelator-derivatised thymidine analog. , 2006, Nuclear medicine and biology.

[53]  S. Eriksson,et al.  3-Carboranyl thymidine analogues (3CTAs) and other boronated nucleosides for boron neutron capture therapy. , 2006, Anti-cancer agents in medicinal chemistry.

[54]  M. Vicente,et al.  Recent progress in the syntheses and biological evaluation of boronated porphyrins for boron neutron-capture therapy. , 2006, Anti-cancer agents in medicinal chemistry.

[55]  G. Bormans,et al.  The Effect of a Methyl or 2-fluoroethyl Substituent at the N-3 Position of Thymidine, 3′-fluoro-3′-deoxythymi-dine and 1-β-D-arabinosylthymine on Their Antiviral and Cytostatic Activity in Cell Culture , 2006, Antiviral chemistry & chemotherapy.

[56]  H. Eklund,et al.  Structure of the substrate complex of thymidine kinase from Ureaplasma urealyticum and investigations of possible drug targets for the enzyme. , 2005, The FEBS journal.

[57]  M. Vicente,et al.  Boron Neutron Capture Therapy of Cancer: Current Status and Future Prospects , 2005, Clinical Cancer Research.

[58]  B. Vig,et al.  Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport. , 2005, Molecular pharmaceutics.

[59]  I. Yamamoto,et al.  Synthesis of N3-substituted uridine and related pyrimidine nucleosides and their antinociceptive effects in mice. , 2005, Chemical & pharmaceutical bulletin.

[60]  G. Schulz,et al.  Structure of a type II thymidine kinase with bound dTTP , 2005, FEBS letters.

[61]  S. Eriksson,et al.  Synthesis and biological evaluation of neutral and zwitterionic 3-carboranyl thymidine analogues for boron neutron capture therapy. , 2005, Journal of medicinal chemistry.

[62]  H. Eklund,et al.  Structures of thymidine kinase 1 of human and mycoplasmic origin , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[63]  S. Eriksson,et al.  Synthesis of ethyleneoxide modified 3-carboranyl thymidine analogues and evaluation of their biochemical, physicochemical, and structural properties. , 2004, Bioorganic & medicinal chemistry.

[64]  S. Eriksson,et al.  Boron-Containing Nucleosides as Potential Delivery Agents for Neutron Capture Therapy of Brain Tumors , 2004, Cancer Research.

[65]  N. Joan Abbott,et al.  Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology , 2004, Neurochemistry International.

[66]  S. Eriksson,et al.  Evaluation of Human Thymidine Kinase 1 Substrates as New Candidates for Boron Neutron Capture Therapy , 2004, Cancer Research.

[67]  S. Eriksson,et al.  The role of thymidine kinases in the activation of pyrimidine nucleoside analogues. , 2004, Mini reviews in medicinal chemistry.

[68]  B. Vig,et al.  Amino Acid Ester Prodrugs of Floxuridine: Synthesis and Effects of Structure, Stereochemistry, and Site of Esterification on the Rate of Hydrolysis , 2003, Pharmaceutical Research.

[69]  K. Edwards,et al.  Ligand Liposomes and Boron Neutron Capture Therapy , 2004, Journal of Neuro-Oncology.

[70]  S. Adelstein,et al.  Radionuclide therapy with iodine-125 and other auger-electron-emitting radionuclides: experimental models and clinical applications. , 2003, Cancer biotherapy & radiopharmaceuticals.

[71]  S. Kahl,et al.  Synthesis of ether- and carbon-linked polycarboranyl porphyrin dimers for cancer therapies , 2003 .

[72]  A. Marra,et al.  Novel carboranyl C-glycosides for the treatment of cancer by boron neutron capture therapy. , 2003, Chemistry.

[73]  K. Johansson,et al.  Structure and function of cellular deoxyribonucleoside kinases , 2002, Cellular and Molecular Life Sciences CMLS.

[74]  U. Griesbach,et al.  Novel Carboranes with a DNA Binding Unit for the Treatment of Cancer by Boron Neutron Capture Therapy , 2002, Chembiochem : a European journal of chemical biology.

[75]  J. Mackey,et al.  Nucleoside analogues: mechanisms of drug resistance and reversal strategies , 2001, Leukemia.

[76]  G. Kabalka,et al.  Synthesis of a Water Soluble Carborane Containing Amino Acid as a Potential Therapeutic Agent , 2001 .

[77]  E. Seregni,et al.  Uptake of Tritiated Thymidine, Deoxyglucose and Methionine in Three Lung Cancer Cell Lines: Deoxyglucose Uptake Mirrors Tritiated Thymidine Uptake , 2000, Tumor Biology.

[78]  S. Eriksson,et al.  Synthesis of 5-(carboranylalkylmercapto)-2'-deoxyuridines and 3-(carboranylalkyl)thymidines and their evaluation as substrates for human thymidine kinases 1 and 2. , 1999, Journal of medicinal chemistry.

[79]  R. Schinazi,et al.  Nucleic acids and nucleosides containing carboranes , 1999 .

[80]  R. Barth,et al.  Synthesis and biological evaluation of boron-containing polyamines as potential agents for neutron capture therapy of brain tumors. , 1999, Journal of medicinal chemistry.

[81]  J. Carlsson,et al.  Uptake of a boronated epidermal growth factor-dextran conjugate in CHO xenografts with and without human EGF-receptor expression. , 1998, Anti-cancer drug design.

[82]  R. Barth,et al.  The Chemistry of Neutron Capture Therapy. , 1998, Chemical reviews.

[83]  R. Barth,et al.  Boron-containing polyamines as DNA targeting agents for neutron capture therapy of brain tumors: synthesis and biological evaluation. , 1997, Journal of medicinal chemistry.

[84]  C. Monneret,et al.  Preparation and anti-HIV activity of N-3-substituted thymidine nucleoside analogs. , 1997, Journal of medicinal chemistry.

[85]  Hugh Davson,et al.  Physiology of the CSF and Blood-Brain Barriers , 1996 .

[86]  S. Eriksson,et al.  Structure-activity relationships for phosphorylation of nucleoside analogs to monophosphates by nucleoside kinases. , 1996, Acta biochimica Polonica.

[87]  I. Hall,et al.  The cytotoxicity of 3'-aminocyanoborane-2', 3'-dideoxypyrimidines in murine and human tissue cultured cell lines. , 1995, Anticancer research.

[88]  Elias S. J. Arnér,et al.  Mammalian deoxyribonucleoside kinases. , 1995, Pharmacology & therapeutics.

[89]  R. Schinazi,et al.  Boron Containing Pyrimidines, Nucleosides, and Oligonucleotides for Neutron Capture Therapy , 1994 .

[90]  I. Yamamoto,et al.  Preparation and pharmacological evaluation of N3-substituted thymidine derivatives as central depressants. , 1993, Chemical & pharmaceutical bulletin.

[91]  Yoshinori Yamamoto,et al.  Synthesis of carboranes containing nucleoside bases , 1992 .

[92]  Y. Kitade,et al.  Synthesis and anti-human immunodeficiency virus type 1 (HIV-1) activity of 3-substituted derivatives of 3'-azido-3'-deoxythymidine (AZT), and inhibition of HIV-1 reverse transcriptase by their 5'-triphosphates. , 1992, Chemical & pharmaceutical bulletin.

[93]  H. Hojo,et al.  Synthesis of carboranes containing nucleoside bases. Unexpectedly high cytostatic and cytocidal toxicity towards cancer cells , 1992 .

[94]  T. Kelly,et al.  Cell cycle regulation of thymidine kinase: residues near the carboxyl terminus are essential for the specific degradation of the enzyme at mitosis , 1991, Molecular and cellular biology.

[95]  B. Oberg,et al.  Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs. , 1991, Biochemical and biophysical research communications.

[96]  R. Schinazi,et al.  Synthesis of 5-(dihydroxyboryl)-2'-deoxyuridine and related boron-containing pyrimidines , 1985 .

[97]  P. Gröbner,et al.  Thymidine kinase. A novel affinity chromatography of the enzyme and its regulation by phosphorylation in Physarum polycephalum. , 1984, The Journal of biological chemistry.

[98]  L. Gianni,et al.  Pharmacological evaluation of intravenous delivery of 5-bromodeoxyuridine to patients with brain tumors. , 1984, Cancer research.

[99]  C. Lowe,et al.  Some parameters relevant to affinity chromatography on immobilized nucleotides. , 1973, The Biochemical journal.

[100]  C. Anfinsen,et al.  [31] Affinity chromatography , 1971 .